Updated:
Finchley Healthcare Ventures
Finchley Healthcare Ventures (FHCV) is a Canadian venture capital fund founded in 2022 specializing in investments within the rapidly evolving landscape of...
Finchley Healthcare Ventures
Finchley Healthcare Ventures (FHCV) is a Canadian venture capital fund founded in 2022 specializing in investments within the rapidly evolving landscape of life sciences. With a passion for advancing healthcare and a keen focus on fostering innovation, FHCV is dedicated to supporting companies developing new and transformative medicines, as well as investing in other venture capital funds operating in the life sciences sector. FHCV invests in companies that are pushing the boundaries of medical research and development, with a particular emphasis on those developing novel therapies. FHCV seeks out opportunities where breakthrough technologies and transformative ideas have the potential to address significant unmet medical needs and revolutionize patient care. The organization also invests in venture capital funds specializing in life sciences and seeks to leverage their expertise and network to access a diverse range of investment opportunities. This approach allows FHCV to diversify its portfolio while also benefiting from the specialized knowledge and due diligence capabilities of these investment partners.
General information
Firm type
Venture Capital
Year founded
2022
Location
Region
North America
Country
Canada
City
Montreal
Corporate office
Montreal, Quebec, Canada
Principals
David Goodman
Executive Chairman of the Board, Pharmascience Inc.
Pierre Beauparlant
Managing Partner / Venture Partner
Morris Goodman
Co-Founder & Chairman Emeritus, Pharmascience Inc.
Sector focus
Frequently asked questions
Who runs investment decisions at Finchley Healthcare Ventures?
Pierre Beauparlant, Ph.D., leads investment activity. He joined Finchley after serving as a venture partner at Sanderling Ventures, a life-science venture capital fund in the San Francisco Bay area (per firm website). Dr. Beauparlant's background includes roles as CEO of Sanderling portfolio companies PreciThera Inc. and SpecificiT Pharma Inc., as well as Medical Therapeutic Head – Hematology at Novartis Pharmaceuticals Canada. The firm's investment posture is ultimately guided by Dr. David Goodman, Executive Chairman of Pharmascience.
How is Finchley Healthcare Ventures related to Pharmascience?
Finchley operates as a distinct investment vehicle with deep ties to Pharmascience Inc., the Canadian pharmaceutical company co-founded by Morris Goodman in 1983. Dr. David Goodman, who served as CEO of Pharmascience from 2006 to 2022, chairs both entities. Finchley's investment team draws on Pharmascience's network of drug-development, manufacturing, and regulatory experts to support portfolio companies, but its investment capital and decision-making are separate functions.
Does Finchley invest in external venture funds or only make direct deals?
Finchley maintains a dual approach. The firm makes direct equity investments in companies developing novel drug therapies and also commits capital to specialized life-sciences venture capital funds. This structure aims to combine proprietary, network-sourced direct opportunities with the broader deal flow and diversification that fund commitments provide.
What stages of drug development does Finchley target?
Finchley will consider companies that are about to begin their first clinical trial as well as those that are further along in development. The firm's stated investment objective is to help companies demonstrate proof of concept in humans for novel therapies that address diseases not adequately served by current treatments (per firm website).
Where does Finchley's underlying investment capital come from?
The primary source of capital is the wealth generated by Pharmascience Inc., a top-tier Canadian pharmaceutical company with significant generic and branded product operations globally. The investment function is an extension of the Goodman family's pharmaceutical enterprise, rather than a fund with external limited partners.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: